DiaMedica Therapeutics Inc’s filing revealed that its 10% Owner STAHLBERG JAN acquired Company’s shares for reported $5.4 million on Jul 23 ’25. In the deal valued at $3.50 per share,1,542,857 shares were bought. As a result of this transaction, STAHLBERG JAN now holds 6,764,465 shares worth roughly $30.37 million.
Then, Von Koch Thomas bought 2,857,142 shares, generating $9,999,997 in total proceeds. Upon buying the shares at $3.50, the 10% Owner now owns 8,383,577 shares.
Before that, JACINTO RICHARD II bought 400,000 shares. DiaMedica Therapeutics Inc shares valued at $1,400,000 were divested by the 10% Owner at a price of $3.50 per share. As a result of the transaction, JACINTO RICHARD II now holds 4,958,823 shares, worth roughly $22.27 million.
H.C. Wainwright initiated its DiaMedica Therapeutics Inc [DMAC] rating to a Buy in a research note published on October 07, 2024; the price target was $7. Oppenheimer also remained covering DMAC and has increased its forecast on June 22, 2023 with a “an Outperform” recommendation from previously “Perform” rating. Oppenheimer started covering the stock on April 09, 2021. It rated DMAC as “an Outperform”.
Price Performance Review of DMAC
On Tuesday, DiaMedica Therapeutics Inc [NASDAQ:DMAC] saw its stock jump 2.98% to $4.49. Over the last five days, the stock has lost -2.18%. DiaMedica Therapeutics Inc shares have risen nearly 30.14% since the year began. Nevertheless, the stocks have fallen -17.31% over the past one year.
How much short interest is there in DiaMedica Therapeutics Inc?
A steep rise in short interest was recorded in DiaMedica Therapeutics Inc stocks on 2025-07-15, growing by 1.18 million shares to a total of 2.41 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 1.23 million shares. There was a rise of 48.91%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on February 17, 2021 when ROTH Capital began covering the stock and recommended ‘”a Buy”‘ rating along with a $38 price target.
